Day: February 28, 2025

Nordic Fibreboard AS unaudited financial report for the Q4 and 12 months of 2024

Written by Customer Service on February 28, 2025. Posted in Earnings Releases And Operating Results.

MANAGEMENT REPORT Consolidated net sales for Q4 2024 were € 1.51 million, which was a 15% increase compared to the same period last year (Q4 2023: € 1.31 million). The main business area is Nordic Fibreboard Ltd, the production and wholesale of fibreboard, which accounted for the majority of the Group`s revenue in Q4 2024. The second segment is the management of the real estate on Suur-Jõe street in Pärnu, the share of sales revenue of which is 0.10% on total sales in the 4th quarter of 2024 (0.95% in Q4 2023). Sales revenue in 2024 Q4 increased by € 212 thousand compared to the Q4 2023. Sales volume from Scandinavian construction sector declined compared to the Q4 2023, while orders from industrial clients have shown an growth trend. An unexpected force majeure situation forced the factory to temporarily close in December, resulting...

Lifeward to Report Fourth Quarter and Fiscal Year-End 2024 Financial Results on March 7, 2025

Written by Customer Service on February 28, 2025. Posted in Public Companies.

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 28, 2025 (GLOBE NEWSWIRE) — Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its fourth quarter and fiscal year-end financial results before the markets open on Friday, March 7, 2025. Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results. To access the call, analysts and investors may utilize the following:Toll free (U.S.) 1-833-316-0561International (U.S) 1-412-317-0690Germany 0800-6647650Israel 1-80-9212373Access Code Please reference the “Lifeward Earnings Call”The...

SailPoint Announces Date of Fiscal Q4 and Full Year 2025 Earnings Conference Call

Written by Customer Service on February 28, 2025. Posted in Public Companies.

AUSTIN, Texas, Feb. 28, 2025 (GLOBE NEWSWIRE) — SailPoint, Inc. (Nasdaq: SAIL), a leader in enterprise identity security, will report its fiscal fourth quarter and full year 2025 financial results before the US markets open on Wednesday, March 26, 2025. SailPoint will host a conference call that day at 8:30 a.m. Eastern Time to discuss the results. A live webcast of the conference call and the financial results press release will be available on SailPoint’s website at https://investors.sailpoint.com. An audio replay of the conference call will be available on the investor relations website for one year. About SailPoint SailPoint, Inc. (Nasdaq: SAIL) equips the modern enterprise to seamlessly manage and secure access to applications and data through the lens of identity – at speed and scale. As a category leader, we continuously...

Nayax Announces the Acquisition of UPPay

Written by Customer Service on February 28, 2025. Posted in Mergers And Acquisitions.

Nayax announces strategic acquisition of Brazil-based UPPay, strengthening its position in the Latin American market HERZLIYA, Israel, Feb. 28, 2025 (GLOBE NEWSWIRE) — Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX), a global commerce enablement and payments platform designed to help merchants scale their business by simplifying payments and maximizing loyalty, today announced the acquisition of UPPay, a leading digital payment and telemetry provider for automated self-service coffee machines in Brazil. This strategic acquisition will significantly increase Nayax’s Brazilian footprint and unlock new market opportunities across Latin America with a sophisticated suite of affordable solutions. UPPay offers an economical, scalable, customizable, and comprehensive telemetry solution for automated self-service machines, making it ideal for businesses...

TeraWulf Reports Fourth Quarter and Full Year 2024 Results

Written by Customer Service on February 28, 2025. Posted in Earnings Releases And Operating Results.

Announced strategic expansion into AI-driven HPC hosting with long-term data center leases expected to generate $1 billion in cumulative revenue over initial 10-year contract terms Annual revenue and non-GAAP adjusted EBITDA increase 102% and 89% year-over-year, respectively Expanded self-mining operating capacity by 94% year-over-year to 9.7 EH/s as compared to 5.0 EH/s in 2023 Strengthened the Balance Sheet with cash and bitcoin holdings of $275 million as of December 31, 2024 Proactively repaid legacy term loan debt ahead of schedule and financed HPC hosting growth with new 2.75% convertible notes issuance due 2030 Authorized $200 million share repurchase program and executed over $150 million of repurchases equivalent to over 24 million shares of Common Stock to date EASTON, Md., Feb. 28, 2025 (GLOBE NEWSWIRE) — TeraWulf Inc....

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Written by Customer Service on February 28, 2025. Posted in Earnings Releases And Operating Results.

— Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study — — Completed enrollment of the double-blinded portion of the Phase 3 SYNCHRONY Real-World Study evaluating EFX in patients with either MASLD or MASH — — Presented New Analyses of Week 96 Phase 2b HARMONY in Patients with Pre-Cirrhotic (F2-F3) MASH at the 75th Annual AASLD The Liver Meeting® 2024 — SOUTH SAN FRANCISCO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today reported fourth quarter and full year financial results for the period...

Boralex reports net earnings of $74 million for fiscal 2024 and continues construction of its large-scale projects in Québec, Ontario and the United Kingdom

Written by Customer Service on February 28, 2025. Posted in Earnings Releases And Operating Results.

MONTREAL, Feb. 28, 2025 (GLOBE NEWSWIRE) — Boralex Inc. (“Boralex” or the “Corporation”) (TSX: BLX) is pleased to report its results for the three-month period and year ended December 31, 2024. HighlightsFinancial resultsEBITDA(A)1, operating income and net earnings under pressure in Q4-2024 owing to adverse wind and hydropower conditionsProduction 16% (11% on a Combined1 basis)2 lower than in Q4-2023 and 16% (12%) below anticipated production1, due primarily to the adverse climate conditions. For fiscal 2024 overall, production was 5% (2%) lower than in 2023 and 10% (8%) below anticipated production. EBITDA(A) of $169 million ($191 million) for Q4-2024, down $33 million ($38 million) from Q4-2023. For fiscal 2024, EBITDA(A) was $581 million ($670 million), up $3 million (down $5 million) from 2023. The decrease in production...

Opthea Reports Half Year Results and Business Updates

Written by Customer Service on February 28, 2025. Posted in Earnings Releases And Operating Results.

Cash and cash equivalents of $131.9M as of December 31, 2024 Cash runway extends through anticipated topline data readouts of COAST (early 2Q CY25) and ShORe (mid-CY25) MELBOURNE, Australia and PRINCETON, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) — Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced financial results for the six months ended December 31, 2024, and highlighted recent corporate and clinical updates. “Opthea is making significant progress on its mission to deliver superior vision to patients with wet AMD enabling them to live fuller and healthier lives,” said Frederic Guerard, PharmD, Chief Executive Officer of...

Fairfax Announces Intention to Redeem Cumulative Preferred Shares, Series E, F & M

Written by Customer Service on February 28, 2025. Posted in Dividend Reports And Estimates.

TORONTO, Feb. 28, 2025 (GLOBE NEWSWIRE) — Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U) today announced its intention to redeem (i) all of its 5,440,132 outstanding Cumulative 5-Year Rate Reset Preferred Shares, Series E (the “Series E Shares”), (ii) all of its 2,099,046 outstanding Cumulative Floating Rate Preferred Shares, Series F (the “Series F Shares”), and (iii) all of its 9,200,000 outstanding Cumulative 5-Year Rate Reset Preferred Shares, Series M (the “Series M Shares” and, collectively with the Series E Shares and the Series F Shares, the “Preferred Shares”) on March 31, 2025 (the “Redemption Date”) at a redemption price equal to C$25.00 per share, for an aggregate total amount of approximately C$420.5 million, together with all accrued and unpaid dividends up to but excluding the Redemption Date...

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,’ to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

Written by Customer Service on February 28, 2025. Posted in Public Companies.

New website launched in honor of Rare Disease Day, Feb. 28, 2025 Awareness campaign includes educational resources and testing information for individuals with suspected NPC. CELEBRATION, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies to people living with rare disease, today announced, on Rare Disease Day, the launch of a new disease state awareness campaign, ’Learn NPC, Read Between the Signs,’ to highlight the need for early recognition and diagnosis due to the heterogeneity of symptoms related to Niemann-Pick disease type C (NPC). NPC is an ultra-rare, progressive, and neurodegenerative lysosomal storage disorder with varying age of onset and symptom presentation, often making the pathway to diagnosis difficult.“We...

Day: February 28, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals